Cyclacel Pharmaceuticals, Inc.
CYCCNASDAQHealthcare
$6.37
$-0.41(-5.98%)
Market Cap$10608329
P/E Ratio—
52W High$597.59973
52W Low$3.0801
Cyclacel Pharmaceuticals, Inc. (CYCC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CYCC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.75M | $0.04M | $0.42M | $0.00M | $0.00M |
| Cost of Revenue | $0.61M | $0.00M | $0.00M | $0.03M | $0.04M |
| Gross Profit | $0.14M | $0.04M | $0.42M | ($0.03M) | ($0.04M) |
| Gross Margin %(computed) | 18.47% | 100.00% | 100.00% | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.85M | $6.66M | $19.16M | $20.27M | $14.93M |
| G&A Expenses | $7.72M | $5.39M | $6.72M | $7.38M | $7.46M |
| Total Operating Expenses | $8.56M | $12.05M | $25.87M | $27.66M | $22.39M |
| Operating Income | ($8.43M) | ($12.00M) | ($25.45M) | ($27.66M) | ($22.94M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.06M | $0.01M | $0.27M | $0.21M | $0.02M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($3.00M) | ($11.99M) | ($25.55M) | ($25.91M) | ($22.18M) |
| Income Tax Expense | ($0.01M) | ($0.78M) | ($3.00M) | ($4.72M) | ($3.85M) |
| Net Income | ($3.00M) | ($11.21M) | ($22.55M) | ($21.20M) | ($18.89M) |
| Net Margin %(computed) | -401.34% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-6.45 | $-1.36 | $-28.67 | $-28.50 | $-32.10 |
| Wtd Avg Shares | 2.19M | 8.31M | 0.80M | 0.75M | 0.60M |
| EBITDA | ($8.43M) | ($12.00M) | ($25.42M) | ($27.62M) | ($22.69M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Cyclacel Pharmaceuticals, Inc. data
About Cyclacel Pharmaceuticals, Inc. (CYCC) Income Statement
Cyclacel Pharmaceuticals, Inc. (CYCC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CYCC reported revenue of $0.00B, gross profit of $0.00B (gross margin 18.47%), and net income of ($0.00B) — a net profit margin of -401.34%.
Frequently asked questions
CYCC · 4 questionsCyclacel Pharmaceuticals, Inc. (CYCC) reported revenue of $0.00B for 2025, up 1637.2% year-over-year.
CYCC revenueCYCC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09